

# 1st Biennial Meeting of Asian Society of Gynecologic Oncology

Educational Session sponsored by MSD

## Policy Implementation of HPV vaccine

Saturday, 21 November 2009

15:40 - 17:00, Room 706, 7th Floor

Toshi Center Hotel, Japan

\* Reception will take place from 20:00  
Venue will be announced during educational session.



GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] is a registered trademark of Merck & Co., Whitehouse Station, NJ, USA



한국엠에스디 (주)

Copyright © 2009 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA All Rights Reserved  
서울특별시 마포구 공덕동 168 미래에셋생명빌딩 11층 (전화) 02-6363-0114 <http://www.msd-korea.com> 11-2011-GRD-2009-KR-5380-M

We cordially invite you to this special session, where two leaders from the field will explore the government policy aspects of planning vaccination programs in regards to;

- ▶ How extensively and fast the HPV vaccine was implemented and funded globally,
- ▶ Why the vaccination is important considering the future health impact ,
- ▶ How Governments can use health economics as an aid to decision-making for the National Immunisation Program
- ▶ Recent outcome of Health Economic Value of HPV vaccine.

Saturday, 21 November 2009

Topic	Speaker	Time
Global Recommendation and Funding Status of HPV Vaccine (20min)	Dr. Randy Hyer	15:50 -16:10
Health economics for non-economists: Health economics to decision-making for National Immunisation Program (30min)	Prof. Luke Connelly	16:10 - 16:40
Q&A & Discussion		16:40 - 17:00

#### Speaker

**Dr. Randy Hyer**  
Senior Medical Director  
Banyu Pharmaceutical Company

**Prof. Luke Connelly**  
Professor of Health Economics  
Director (UQ node), Australian Centre for  
Economic Research on Health  
University of Queensland

